カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の抗体薬物複合体市場2023-2030：用途別（血液がん、乳がん）、技術別（切断可能型、非切断可能型）、地域別

【英語タイトル】Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology ({Type-Cleavable, Non-cleavable}), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23JUN011）・商品コード：GRV23JUN011
・発行会社（調査会社）：Grand View Research
・発行日：2023年5月18日
・ページ数：135
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥892,500見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,042,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,342,500見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Grand View Research社の市場調査書によると、世界の抗体薬物複合体市場規模が、予測期間中に年平均11.2％増加し、2030年までに223.5億ドルへ達すると見込まれています。本調査書では、抗体薬物複合体の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、用途別（血液がん、乳がん、尿路上皮/膀胱がん、その他）分析、種類別（切断可能型リンカー、非切断可能型リンカー、リンカーレス）分析、リンカー技術別（Vc（バリン-シトルリン）、ヒドラゾン、その他）分析、ペイロード技術別（Mmae、Mmaf、Dm4、カンプトテシン、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋中南米、中東・アフリカ）分析、競争状況などについて調査・分析し、まとめています。なお、こちらに掲載されている企業情報には、Takeda Pharmaceutical Company Limited、F.Hoffmann-La Roche Ltd.、Pfizer, Inc.、Astrazeneca、Gilead Sciences, Inc.、Astellas Pharma Inc.、Seagen, Inc.、Daiichi Sankyo Company, Limited、Glaxosmithkline Plc.、Adc Therapeutics Sa、Synaffix Bvなどが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・世界抗体薬物複合体の市場規模：用途別
- 血液がんにおける市場規模
- 乳がんにおける市場規模
- 尿路上皮/膀胱がんにおける市場規模
- その他用途における市場規模
・世界抗体薬物複合体の市場規模：種類別
- 切断可能型リンカー抗体薬物複合体の市場規模
- 非切断可能型リンカー抗体薬物複合体の市場規模
- リンカーレス抗体薬物複合体の市場規模
・世界抗体薬物複合体の市場規模：リンカー技術別
- Vc（バリン-シトルリン）における市場規模
- ヒドラゾンにおける市場規模
- その他リンカー技術における市場規模
・世界抗体薬物複合体の市場規模：ペイロード技術別
- Mmaeにおける市場規模
- Mmafにおける市場規模
- Dm4における市場規模
- カンプトテシンにおける市場規模
- その他ペイロード技術における市場規模
・世界抗体薬物複合体の市場規模：地域別
- 北米の抗体薬物複合体市場規模
- ヨーロッパの抗体薬物複合体市場規模
- アジア太平洋の抗体薬物複合体市場規模
- 中南米の抗体薬物複合体市場規模
- 中東・アフリカの抗体薬物複合体市場規模
・競争状況

抗体薬物複合体市場の成長と動向

Grand View Research, Inc.の最新レポートによると、抗体薬物複合体の世界市場規模は2030年までに223.5億米ドルに達し、予測期間中の年平均成長率は11.2%を記録すると予測されています。強力なパイプライン製品の存在と主要企業による戦略的イニシアティブが、予測期間中の市場成長を促進すると予想されます。

ADC Therapeutics社、Seagen社、武田薬品工業株式会社、F. Hoffmann-La Roche社、AstraZeneca社、第一三共社などが、製品の開発・商業化のために共同研究を行っています。例えば、2022年2月、Mersana Therapeutics社は、Johnson & Johnson社の子会社であるJanssen Pharmaceutical Companies社と、様々ながんを治療する新規ADCの研究開発で提携しました。この契約に基づき、JanssenはMersana Therapeutics社に契約一時金4,000万米ドルと、新規ADC開発のためのマイルストーンとして10億米ドル以上を支払う可能性があります。

製薬企業による新規抗体薬物複合体の開発のための広範な研究と資金調達の増加は、市場の成長を促進すると予測されています。例えば、2021年4月、Adcendo社とAdcentrx社という2つの新しい新興企業が、がん治療への新しいアプローチによるADC開発のために約1億1,200万米ドルの資金を調達しました。Adcendo社は、薬物送達体の役割を果たすエンドサイトーシス受容体を標的とする新しいADCの開発で5,100万米ドルを調達しました。Adcentrx社は、ADC研究プログラムのために5,000万米ドルを調達しました。

さらに、2022年3月、ImmunoGen社は、卵巣がん患者の単剤療法として使用するミルベツキシマブ・ソラブタンシンの生物学的製剤許可申請（BLA）を米国FDAに提出したと発表しました。この製剤は、α結合抗体、開裂可能なリンカー、ペイロードとしてメイタンシノイドDM4から構成され、標的とするがん細胞を殺傷します。

ADCに対する厳しい償還政策は、モノクローナル抗体療法や化学療法のような代替的な従来の治療と比較して、ADCの治療に関連する高コストのため、市場の成長を抑制する可能性があります。この治療費の高さが償還の妨げになると予想されます。例えば、2020年2月、アイルランドのNational Centre for Pharmaco economicsは、Rocheのカドサイラ（トラスツズマブ・エムタンシン）について、その費用対効果の低さを理由に、償還検討に対して否定的なレビューを行いました。

高齢者人口の増加と多発性骨髄腫（MM）などの疾患の有病率の増加は、ADCの需要を促進し、予測期間中の市場成長を促進すると予想されます。多発性骨髄腫（MM）は高齢化社会の疾患であり、2021年には30,000人近いMMの新規症例が診断されました。多発性骨髄腫と診断された患者の年齢中央値は70歳です。そのため、多発性骨髄腫治療用の新しいADCの導入が市場の成長を後押しすると期待されています。例えば、2020年8月、FDAは再発または難治性の多発性骨髄腫を治療する単剤療法としてグラクソ・スミスクライン社のBLENREPを承認しました。ブレンレップは、多発性骨髄腫の治療薬として承認された最初の抗BCMA療法です。

抗体薬物複合体市場レポートハイライト

– 乳がんが2022年に50.61%の最大売上シェアを占めましたが、これは乳がんの有病率の高さと乳がん治療用の複数のADC製品が利用可能であることなどによります。

– 市販ADC製品における開裂可能リンカー技術の採用が増加していること、および他のリンカー技術よりも開裂可能リンカーの使用に関連する利点があることから、開裂可能リンカー部門は2022年に65.20%の最大売上シェアを占めました。

– リンカー技術の種類別では、SMCC、SPP、MCC、マレイミドテトラペプチド、CL2A、MC（マレイミドカプロイル）など、ペイロードを標的部位に送達するために使用される非常に効果的なリンカーが市場に多数存在するため、その他分野が市場で首位に立ちました。

– 北米は、Pfizer社、Gilead Life Sciences社、Seagen社などの主要製薬企業の存在と、新規ADC開発のための戦略的イニシアチブのため、2022年の収益シェアで53.29%を占めました。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Segment Definitions
1.1.1.1 Application Segment
1.1.1.2 Technology Segment
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Gvr’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Technology And Application Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation And Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends And Outlook
3.4. Market Dynamics
3.4.1. Presence Of Strong Product Pipeline
3.4.2. Growing Geriatric Population Base
3.4.3. Increasing Incidence And Prevalence Of Cancer
3.5. Market Restraint Analysis
3.5.1. High Manufacturing Cost And Downstream Processing Challenges For Adcs
3.5.2. Analytical Challenges For Adc
3.5.3. Stringent Reimbursement Policies For Adcs
3.6. Business Environment Analysis
3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. Covid-19 Impact Analysis
3.7. Qualitative Analysis For Adc Development Platforms
3.7.1. Creative Biolabs
3.7.2. Mersana Therapeutics
3.7.3. Heidelberg Pharma
3.7.4. Synaffix Bv
3.7.5. Nbe Therapeutics
3.7.6. Veraxa
3.7.7. Tubulis Gmbh
3.7.8. Byondis Platform
3.7.9. Immunogen, Inc.
3.7.10. Remegen
3.7.11. Wuxi Biologics
3.7.12. Merck Kgaa
3.7.13. Ambrx
Chapter 4. Antibody Drug Conjugates Market: Segment Analysis By Application, 2018 – 2030 (USD Million)
4.1. Antibody Drug Conjugates Market: Application Movement Analysis
4.2. Blood Cancer
4.2.1. Blood Cancer Market, 2018 – 2030 (USD Million)
4.2.2. Leukemia
4.2.2.1. Leukemia Market, 2018 – 2030 (USD Million)
4.2.3. Multiple Myeloma
4.2.3.1. Multiple Myeloma Market, 2018 – 2030 (USD Million)
4.2.4. Lymphoma
4.2.4.1. Lymphoma Market, 2018 – 2030 (USD Million)
4.3. Breast Cancer
4.4. Urothelial/Bladder Cancer
4.4.1. Urothelial/Bladder Cancer Market, 2018 – 2030 (USD Million)
4.5. Others
4.5.1. Others Market, 2018 – 2030 (USD Million)
Chapter 5. Antibody Drug Conjugates Market: Segment Analysis By Technology, 2018 – 2030 (USD Million)
5.1. Antibody Drug Conjugates Market: Technology Movement Analysis
5.2. By Type
5.2.1. Cleavable Linker
5.2.1.1. Cleavable Linker Market, 2018 – 2030 (USD Million)
5.2.2. Non-Cleavable Linker
5.2.2.1. Non-Cleavable Linker Market, 2018 – 2030 (USD Million)
5.2.3. Linkerless
5.2.3.1. Linkerless Market, 2018 – 2030 (USD Million)
5.3. By Linker Technology
5.3.1. Vc (Valine-Citrulline)
5.3.1.1. Vc Market, 2018 – 2030 (USD Million)
5.3.2. Sulfo-Spdb
5.3.2.1. Sulfo-Spdb Market, 2018 – 2030 (USD Million)
5.3.3. Va (Valine Alanine)
5.3.3.1. Va (Valine Alanine) Market, 2018 – 2030 (USD Million)
5.3.4. Hydrazone
5.3.4.1. Hydrazone Market, 2018 – 2030 (USD Million)
5.3.5. Others
5.3.5.1. Others Market, 2018 – 2030 (USD Million)
5.4. By Payload Technology
5.4.1. Mmae
5.4.1.1. Mmae Market, 2018 – 2030 (USD Million)
5.4.2. Mmaf
5.4.2.1. Mmaf Market, 2018 – 2030 (USD Million)
5.4.3. Dm4
5.4.3.1. Dm4 Market, 2018 – 2030 (USD Million)
5.4.4. Camptothecin
5.4.4.1. Camptothecin Market, 2018 – 2030 (USD Million)
5.4.5. Others
5.4.5.1. Others Market, 2018 – 2030 (USD Million)
Chapter 6. Antibody Drug Conjugates Market: Regional Analysis, 2018 – 2030 (USD Million)
6.1. Antibody Drug Conjugates Market Share By Region, 2022 & 2030
6.2. North America
6.2.1. Swot Analysis
6.2.2. North America Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.2.3. U.S.
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. Reimbursement Scenario
6.2.3.6. U.S. Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.2.4. Canada
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Competitive Scenario
6.2.4.4. Regulatory Framework
6.2.4.5. Reimbursement Scenario
6.2.4.6. Canada Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.3. Europe
6.3.1. Swot Analysis
6.3.2. Europe Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. Reimbursement Scenario
6.3.3.6. Germany Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.3.4. Uk
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Reimbursement Scenario
6.3.4.6. Uk Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.3.5. France
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. Reimbursement Scenario
6.3.5.6. France Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.3.6. Italy
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Regulatory Framework
6.3.6.5. Reimbursement Scenario
6.3.6.6. Italy Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.3.7. Spain
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Regulatory Framework
6.3.7.5. Reimbursement Scenario
6.3.7.6. Spain Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.3.8. Denmark
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Regulatory Framework
6.3.8.5. Reimbursement Scenario
6.3.8.6. Denmark Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.3.9. Sweden
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Regulatory Framework
6.3.9.5. Reimbursement Scenario
6.3.9.6. Sweden Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.3.10. Norway
6.3.10.1. Key Country Dynamics
6.3.10.2. Target Disease Prevalence
6.3.10.3. Competitive Scenario
6.3.10.4. Regulatory Framework
6.3.10.5. Reimbursement Scenario
6.3.10.6. Norway Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Swot Analysis
6.4.2. Asia Pacific Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.4.3. Japan
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Reimbursement Scenario
6.4.3.6. Japan Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.4.4. China
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. Reimbursement Scenario
6.4.4.6. China Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.4.5. India
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Regulatory Framework
6.4.5.5. Reimbursement Scenario
6.4.5.6. India Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.4.6. South Korea
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Regulatory Framework
6.4.6.5. Reimbursement Scenario
6.4.6.6. South Korea Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.4.7. Australia
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. Regulatory Framework
6.4.7.5. Reimbursement Scenario
6.4.7.6. Australia Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.4.8. Thailand
6.4.8.1. Key Country Dynamics
6.4.8.2. Target Disease Prevalence
6.4.8.3. Competitive Scenario
6.4.8.4. Regulatory Framework
6.4.8.5. Reimbursement Scenario
6.4.8.6. Thailand Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.5. Latin America
6.5.1. Swot Analysis
6.5.2. Latin America Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.5.3. Brazil
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Reimbursement Scenario
6.5.3.6. Brazil Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Regulatory Framework
6.5.4.5. Reimbursement Scenario
6.5.4.6. Mexico Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.5.5. Argentina
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Competitive Scenario
6.5.5.4. Regulatory Framework
6.5.5.5. Reimbursement Scenario
6.5.5.6. Argentina Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.6. Mea
6.6.1. Swot Analysis
6.6.2. Mea Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.6.3. South Africa
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. Reimbursement Scenario
6.6.3.6. South Africa Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.6.4. Saudi Arabia
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Reimbursement Scenario
6.6.4.6. Saudi Arabia Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.6.5. Uae
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. Reimbursement Scenario
6.6.5.6. Uae Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
6.6.6. Kuwait
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Competitive Scenario
6.6.6.4. Regulatory Framework
6.6.6.5. Reimbursement Scenario
6.6.6.6. Kuwait Antibody Drug Conjugates Market, 2018 – 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.2.1 New Product Launch
7.2.2 Partnerships
7.2.3 Acquisition
7.2.4 Collaboration
7.2.5 Funding
7.3 Key Company Market Share Analysis, 2022
7.4 Company Profiles
7.4.1 Takeda Pharmaceutical Company Limited
7.4.1.1 Company Overview
7.4.1.2 Financial Performance
7.4.1.3 Product Benchmarking
7.4.1.4 Strategic Initiatives
7.4.2 F.Hoffmann-La Roche Ltd.
7.4.2.1 Company Overview
7.4.2.2 Financial Performance
7.4.2.3 Product Benchmarking
7.4.2.4 Strategic Initiatives
7.4.3 Pfizer, Inc.
7.4.3.1 Company Overview
7.4.3.2 Financial Performance
7.4.3.3 Product Benchmarking
7.4.3.4 Strategic Initiatives
7.4.4 Astrazeneca
7.4.4.1 Company Overview
7.4.4.2 Product Benchmarking
7.4.4.3 Strategic Initiatives
7.4.5 Gilead Sciences, Inc.
7.4.5.1 Company Overview
7.4.5.2 Financial Performance
7.4.5.3 Product Benchmarking
7.4.5.4 Strategic Initiatives
7.4.6 Astellas Pharma Inc.
7.4.6.1 Company Overview
7.4.6.2 Financial Performance
7.4.6.3 Product Benchmarking
7.4.6.4 Strategic Initiatives
7.4.7 Seagen, Inc.
7.4.7.1 Company Overview
7.4.7.2 Financial Performance
7.4.7.3 Product Benchmarking
7.4.7.4 Strategic Initiatives
7.4.8 Daiichi Sankyo Company, Limited
7.4.8.1 Company Overview
7.4.8.2 Financial Performance
7.4.8.3 Product Benchmarking
7.4.8.4 Strategic Initiatives
7.4.9 Glaxosmithkline Plc.
7.4.9.1 Company Overview
7.4.9.2 Financial Performance
7.4.9.3 Product Benchmarking
7.4.9.4 Strategic Initiatives
7.4.10 Adc Therapeutics Sa
7.4.10.1 Company Overview
7.4.10.2 Financial Performance
7.4.10.3 Product Benchmarking
7.4.10.4 Strategic Initiatives
7.4.11 Synaffix Bv
7.4.11.1 Company Overview
7.4.11.2 Financial Performance
7.4.11.3 Product Benchmarking
7.4.11.4 Strategic Initiatives
Chapter 8. Kol Recommendations/ Conclusion

List of Tables

TABLE 1 List of abbreviation
TABLE 2 List of secondary sources
TABLE 3 Global antibody-drug conjugates market estimates and forecasts, by region, 2018 - 2030 (USD Million)
TABLE 4 Global antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 5 Global antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 6 Global antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 7 Global antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 8 North America antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
TABLE 9 North America antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 10 North America antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 11 North America antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 12 North America antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 13 U.S. antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 14 U.S. antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 15 U.S. antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 16 U.S. antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 17 Canada antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 18 Canada antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 19 Canada antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 20 Canada antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 21 Europe antibody-drug conjugates market estimates and forecasts, by country, 2018 - 2030 (USD Million)
TABLE 22 Europe antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 23 Europe antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 24 Europe antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 25 Europe antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 26 U.K. antibody-drug conjugates market estimates and forecasts, by application, 2017 - 62028 (USD Million)
TABLE 27 UK antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 28 UK antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 29 UK antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 30 Germany antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 31 Germany antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 32 Germany antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 33 Germany antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 34 France antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 35 France antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 36 France antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 37 France antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 38 Italy antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 39 Italy antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 40 Italy antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 41 Italy antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 42 Spain antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 43 Spain antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 44 Spain antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 45 Spain antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 46 Denmark antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 47 Denmark antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 48 Denmark antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 49 Denmark antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 50 Sweden antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 51 Sweden antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 52 Sweden antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 53 Sweden antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 54 Norway antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 55 Norway antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 56 Norway antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 57 Norway antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 58 Asia Pacific antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 59 Asia Pacific antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 60 Asia Pacific antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 61 Asia Pacific antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 62 Japan antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 63 Japan antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 64 Japan antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 65 Japan antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 66 China antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 67 China antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 68 China antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 69 China antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 70 India antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 71 India antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 72 India antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 73 India antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 74 Australia antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 75 Australia antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 76 Australia antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 77 Australia antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 78 South Korea antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 79 South Korea antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 80 South Korea antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 81 South Korea antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 82 Thailand antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 83 Thailand antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 84 Thailand antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 85 Thailand antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 86 Latin America antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 87 Latin America antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 88 Latin America antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 89 Latin America antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 90 Brazil antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 91 Brazil antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 92 Brazil antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 93 Brazil antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 94 Mexico antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 95 Mexico antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 96 Mexico antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 97 Mexico antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 98 Argentina antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 99 Argentina antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 100 Argentina antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 101 Argentina antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 102 MEA antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 103 MEA antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 104 MEA antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 105 MEA antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 106 South Africa antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 107 South Africa antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 108 South Africa antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 109 South Africa antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 110 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 111 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 112 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 113 Saudi Arabia antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 114 UAE antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 115 UAE antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 116 UAE antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 117 UAE antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 118 Kuwait antibody-drug conjugates market estimates and forecasts, by application, 2018 - 2030 (USD Million)
TABLE 119 Kuwait antibody-drug conjugates market estimates and forecasts, by technology type, 2018 - 2030 (USD Million)
TABLE 120 Kuwait antibody-drug conjugates market estimates and forecasts, by linker technology, 2018 - 2030 (USD Million)
TABLE 121 Kuwait antibody-drug conjugates market estimates and forecasts, by payload technology, 2018 - 2030 (USD Million)
TABLE 122 List of key distributors
TABLE 123 List of key emerging companies/technology disruptors/innovators

★調査レポート[世界の抗体薬物複合体市場2023-2030：用途別（血液がん、乳がん）、技術別（切断可能型、非切断可能型）、地域別] (コード：GRV23JUN011)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の抗体薬物複合体市場2023-2030：用途別（血液がん、乳がん）、技術別（切断可能型、非切断可能型）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のペプチド薬物複合体（PDC）市場（2023-2030）：製品別（ルテチウム、メルフルフェン、ANG1005、BT1718、CBX-12、その他）、種類別（診断薬、治療薬）、地域別
  • 世界のオンコロジーベースIn-vivo CRO市場2023-2030：疾患別（血液がん、固形がん）、地域別
  • 世界のカスタム抗体市場2023-2030：種類別（モノクローナル）、サービス別（抗体開発）、ソース別（ネズミ）、用途別、エンドユーザー別、地域別
  • 世界のペプチドマイクロアレイ市場2023-2030：用途別（疾患診断、タンパク質機能解析）、種類別（機器、サービス）、エンドユーザー別、地域別
  • 世界のラベルフリーアレイシステム市場2023-2030：種類別（表面プラズモン共鳴、生体層干渉、細胞誘電分光）、用途別、エンドユーザー別、地域別
  • 世界の微生物API市場2023-2030：ホース別（哺乳類、細菌、真菌）、種類別（抗体、ペプチド、タンパク質）、部位別、分子別、最終用途別、地域別
  • 世界の抗ウイルス薬市場2023-2030：タイプ別（ブランド、ジェネリック）、薬剤クラス別、流通チャネル別（病院薬局、小売薬局）、用途別、地域別
  • 世界の緑内障市場2023-2030：疾患種類別（開放隅角緑内障、閉塞隅角緑内障）、薬剤クラス別（プロスタグランジン類縁体、ベータ遮断薬）、流通チャネル別、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆